Sklice Lotion is an ectoparasiticide used to treat head lice infestations and is considered relevant for easing associated symptomatic distress. The primary therapeutic area is aligned with the official indications for Ivermectin Lotion.

Therapeutic Focus and Symptom Relief

This medication is applied across domains where additional symptomatic support is needed, primarily for conditions characterized by Pediculosis capitis. It is relevant for adults and children 6 months of age and older who require short-term, supportive assistance in eliminating the infestation. The primary indications involve managing conditions presenting with systemic or localized discomfort, helping to ease associated scalp pruritus (intense itching) and irritation, and providing therapeutic support for persistent or resistant infestations.

It is commonly used when symptoms create noticeable physiological strain and interference with daily functioning. When applied in addressing the parasitic condition, the medication contributes to improved day-to-day comfort, helping to ease the overall symptomatic burden during periods of heightened symptoms.

---

Quick Fact: Relief for Scalp Pruritus and Irritation

Who can and cannot use Sklice Lotion?

This section details the officially documented population eligibility rules for Sklice Lotion (Ivermectin 0.5%), based strictly on governmental regulatory information.

---

Eligibility Scope

Category	Eligibility Rule	Classification
Populations for whom use is allowed	Adults and children 6 months of age and older	Established
Populations for whom use is not recommended	Children under 6 months of age	Not Established
Populations for whom use is contraindicated	Patients with known hypersensitivity to ivermectin	Prohibited

---

Restrictions and Special Populations

Sklice Lotion use is subject to specific restrictions and cautions as defined in regulatory labeling.

• Pregnancy and Lactation: Use in pregnant or nursing women is restricted, requiring professional assessment to determine if the potential benefit justifies the potential risk. Caution should be exercised when administered to a nursing mother.
• Anatomical Restrictions: Application is prohibited near the eyes, inside the nose, ear, mouth, or vagina, or on lice in eyebrows or eyelashes. The product is intended only for the scalp and scalp hair.
• Conditional Use: Individuals with any existing skin conditions or sensitivities are advised to consult a healthcare professional before use.
• Organ Impairment: The official US labeling contains no specific warnings or restrictions related to use in patients with hepatic or renal impairment.

The official regulatory profile for Sklice Lotion (ivermectin 0.5%) is characterized by the minimal systemic absorption of the active ingredient following topical application. This low level of entry into the bloodstream is the established basis for the lack of formal interaction warnings in the regulatory documentation, including those related to metabolic pathways or drug transporters.

Interaction Profile Summary

Category	Official Regulatory Documentation
Specific interacting medicines	None explicitly listed in the regulatory documents.
Mechanistic basis of interactions	Minimal systemic absorption, meaning systemic concentrations are significantly lower than those from the oral formulation.
Timing-based interaction rules	None listed. No mandatory spacing of administration is required with other medications, food, or substances.

Population-Specific Constraint

Because of the minimal systemic exposure, the labeling information does not document any standard drug-drug, drug-food, or metabolic interactions. Therefore, the regulatory text features no formally listed contraindicated combinations with other medicines.

The only constraint related to systemic exposure is a population-specific restriction. Use of the lotion is not recommended in pediatric patients under 6 months of age. This measure is enforced due to the potential for increased systemic absorption in this young population, which carries an elevated risk of ivermectin toxicity stemming from the higher ratio of skin surface area to body mass and an immature skin barrier. This restriction is based on a pharmacokinetic risk assessment.

Mechanism of Action: Targeting Invertebrate Neurotransmission

Sklice Lotion's active ingredient, ivermectin, acts by selectively targeting the nervous system of the louse. It functions as an activator of glutamate-gated chloride channels ( GluCl), which are unique to invertebrates, including the head louse.

Binding to these channels forces them to open, causing a massive influx of chloride ions ( Cl^-) into the louse's nerve and muscle cells. This ion influx results in hyperpolarization of the cell membranes, significantly impeding signal transmission at the neuromuscular junction. This cellular consequence rapidly leads to the systemic physiological effect of paralysis in the louse's motor and feeding apparatus.

Furthermore, the residual activity of ivermectin ensures that newly hatched nymphs are affected. The resultant paralysis, specifically of the pharyngeal muscles, prevents feeding. This sustained mechanistic effect causes mortality in the newly emerged nymphs, contributing to the full termination of the parasitic life cycle.

The usage of Sklice Lotion (Ivermectin 0.5% Topical) is defined by a standardized, single-administration protocol. The medication is designed exclusively for topical use on the hair and scalp and must not be administered orally, ophthalmically, or intravaginally.

The treatment regimen consists of a single application only. The prescribed dosage involves applying an amount sufficient to thoroughly coat all hair and the entire scalp, with the maximum dose limited to one full tube (117 g / 4 oz). A second application for the same head lice infestation is not specified within the treatment schedule.

Proper administration requires applying the lotion to dry hair and scalp. Following complete coverage, the product must remain in place for a fixed contact duration of 10 minutes. The rinsing process must be completed using water only. The treatment is approved for use in patients 6 months of age and older, with adult supervision being required for children under 12 years of age.

Following the application and rinsing, the procedural structure mandates that individuals wait a period of 24 hours before using shampoo on the hair. Furthermore, the product is designated for single use, and any unused portion of the tube must be discarded.

Research Evidence / Overview of Studies for Sklice Lotion

This overview summarizes the structure and focus of the clinical research for Sklice Lotion (Ivermectin 0.5%), based on official regulatory reviews and scientific publications. The findings describe group patterns observed in studies and do not provide individual predictions or medical advice.

---

Evidence for use in Head Lice Infestation (Pediculosis Capitis)

Clinical evaluation for the indication of Sklice Lotion was studied in research exploring the treatment of active head lice infestation. Pivotal evidence was drawn from large, multi-center Randomized, Double-Blind, Vehicle-Controlled Phase 3 Trials. These rigorous study designs are used in research exploring the difference between the active medicine and a non-active lotion (vehicle control).

In these studies, researchers measured the louse-free status as the main outcome, which is the absence of any live lice on the scalp at specific check-in times. This outcome reflects a key objective in the trials and is the measure used by regulators to assess whether louse-free status was observed in the studies. Findings reported measurements of louse-free status at Day 15 following a single application. Analysis of the data described different proportions of patients that exhibited louse-free status in the Ivermectin 0.5% group compared to the vehicle group.

---

Follow-up Duration and Durability of Response

The main body of clinical data reflects research exploring short-term symptom changes and outcomes. The primary endpoint for louse-free status was typically measured at Day 15 post-application. This specific follow-up duration was relevant in trials assessing the short-term elimination of the parasite over its life cycle.

For outcomes related to long-term effects, such as the sustained observation of louse-free status, evidence is limited. There is limited information for long-term outcomes or durability of the findings beyond the two-week observation period.

---

Evidence in Pediatric and Special Populations

Sklice Lotion was evaluated in specific age groups to meet regulatory requirements. The populations studied included children 6 months of age and older, as well as adults, who were actively infested with head lice. Research has explored outcomes in these younger patients, and the findings describe group patterns observed in the specific age groups studied.

Data for certain groups remain insufficient. For instance, limited information is available concerning evaluation in older adult patients or patients with comorbid conditions, as these groups were not the focus of the main randomized trials.

Key Studies & References

1. U.S. National Library of Medicine Clinical Trials Registry (ClinicalTrials.gov)
2. Peer-Reviewed Scientific Literature and Systematic Reviews on Ivermectin Lotion Efficacy and Trial Design (via PubMed)
3. NIH PubChem Classification of Ivermectin and Avermectins

Common questions about Sklice Lotion (FAQ)

Q: How quickly should the treatment results of Sklice Lotion be visible?

Studies used to examine the effectiveness of Sklice Lotion often measured the absence of live lice at Day 15 following the single application. These clinical findings describe the patterns observed in patient groups who were found to be louse-free at this two-week mark.

Q: Should Sklice Lotion be applied to the full length of the hair or just the scalp?

The official product instructions describe applying the lotion to the entire head. The application information indicates coating the hair strand from the scalp to the tip.

Q: What happens if Sklice Lotion gets in the eyes, mouth, or nose?

Sklice Lotion is for external use only and is specified to be avoided in sensitive areas like the eyes, nose, ear, mouth, or vagina. Official guidance states that if accidental contact with the eyes occurs, they should be flushed with water. If the lotion is swallowed, contacting emergency medical help or a Poison Control Center is described as necessary.

Q: Why does Sklice Lotion require a prescription?

According to the official regulatory classification, Sklice Lotion is categorized as an Over-the-Counter (OTC) medicine. This status generally means that a prescription is not required for its purchase.

Q: Is Sklice Lotion used for conditions other than head lice, such as scabies?

The product's official indication, as stated in regulatory documents, is for the topical treatment of head lice infestations in patients 6 months of age and older. Sklice Lotion is specifically studied and authorized for this single purpose.

Q: Is Sklice Lotion safe for repeated use over time?

Sklice Lotion is designated in its usage guidelines as a single-treatment application for a head lice infestation. Official product information specifies that repeat use for the same infestation is not indicated without consultation with a healthcare provider.

Q: Is nit combing required after using Sklice Lotion?

Official guidance states that nit combing is not required for the medication to achieve its effects. However, a fine-tooth comb may be used by the individual to remove dead lice and nits if desired.

Q: Are there specific symptoms that should prompt medical attention after using Sklice Lotion?

Official patient information describes stopping use and consulting a healthcare professional if symptoms such as breathing difficulty, a developing rash, persistent eye irritation, or continued skin or scalp irritation occur.

Q: What are the non-active ingredients in Sklice Lotion?

The full formulation is available in official regulatory documents. The inactive ingredients listed include butylated hydroxyanisole, castor oil, cetyl alcohol, citric acid anhydrous, cyclomethicone, glycerin, and lanolin alcohols, among several others.

Q: Is there a different version of Sklice, such as a shampoo or spray?

According to the official documentation, Sklice is formulated as a 0.5% topical suspension, which is described as a lotion. No other dosage forms, such as a shampoo or a spray, are currently referenced in the product labeling.

Q: Can Sklice Lotion cause temporary hair loss or thinning?

The official regulatory review of adverse reactions observed in clinical trials does not list hair loss or thinning among the documented effects. The reported adverse reactions primarily focused on localized skin and eye conditions.

Q: What should be done if too much Sklice Lotion is accidentally applied?

In the event that the lotion is swallowed or there are signs of an overdose, official guidance describes contacting a Poison Control Center or emergency services immediately. Potential symptoms of overdose are described in the patient information.

Q: Is Sklice Lotion oil-based or water-based?

The full composition of Sklice Lotion contains ingredients from multiple sources, including water and various alcohol and oil compounds. The inactive ingredients listed in the product's official documents include olive oil, castor oil, and oleyl alcohol.

Q: Should bedding or clothing be washed after using Sklice Lotion to prevent re-infestation?

Official guidance describes washing or dry-cleaning recently worn clothing, hats, towels, and used bedding in hot water as part of an overall lice management program. This is described as an adjunctive measure.

Q: Can Sklice Lotion cause temporary changes to hair or scalp appearance?

Clinical trial data documents common adverse reactions related to the application site. These include skin conditions such as dry skin and dandruff, which are changes that may affect the appearance of the scalp.

Storage and Disposal Requirements for Sklice Lotion

Storage Conditions

Sklice Lotion must be stored at controlled room temperature, maintaining a range of 68 F to 77 F (20 C to 25 C). The medication must be kept in its original container, which should be tightly closed, and stored away from both excess heat and moisture.

• Prohibited Environments: The product must not be frozen.
• Child Safety: Keep Sklice Lotion and all medicines out of the reach of children.

Disposal Instructions

Sklice Lotion is for single use only; any unused portion of the tube must be discarded after use.

• Restrictions: The medication should not be flushed down the toilet.
• Recommended Method: The best method for discarding unused or expired product is through an authorized medicine take-back program. If a take-back program is unavailable, official guidance recommends preparing the product for household trash disposal.